Results of Operations and Financial Condition. On August 5, 2026, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 27, 2026 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…

Other Events. As previously announced, following receipt of a recent unsolicited acquisition proposal from a party interested in acquiring the Company and multiple other expressions of interest, the Company’s Board of Directors (the “Board”) established a committee of independent directors, which, with the assistance of independent advisors, is evaluating a range of strategic alternatives, including but not limited to a sale of the Company or continued execution of the Company’s standalone pl…

Results of Operations and Financial Condition. On May 6, 2026, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 28, 2026 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Results of Operations and Financial Condition. On March 5, 2026 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Director — Ajay Dhankhar, PhD: Dr. Ajay Dhankhar was appointed as a Class II director of Bioventus Inc.

Results of Operations and Financial Condition. On November 4, 2025, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 27, 2025 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…

Results of Operations and Financial Condition. On August 6, 2025, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 28, 2025 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…

Entry into a Material Definitive Agreement.. On July 31, 2025 (the “Closing Date”), Bioventus LLC, a Delaware limited liability company and subsidiary of Bioventus Inc. (“Bioventus LLC” or the “Company”) and certain of its subsidiaries entered into a Credit Agreement (the “2025 Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, and the lenders and other financial institutions party thereto. Pursuant to the 2025 Credit Agreement, the Company entered into a…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Results of Operations and Financial Condition. On May 6, 2025, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 29, 2025 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Results of Operations and Financial Condition. On March 11, 2025 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)…

Completion of Acquisition or Disposition of Assets. As previously disclosed in a Current Report on Form 8-K filed by Bioventus Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on October 4, 2024 (the “Initial Form 8-K”), Bioventus LLC, a Delaware limited liability company (“BV LLC”) and a subsidiary of the Company, together with two of BV LLC's subsidiaries, Bioness Inc., a Delaware corporation (“Bioness”), and Bioventus Cooperatief, U.A., a company organized under…

Results of Operations and Financial Condition. On November 5, 2024, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 28, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…

Entry into a Material Definitive Agreement. On September 30, 2024 , Bioventus LLC, a Delaware limited liability company (“Bioventus”) and a subsidiary of Bioventus Inc. (the “Company”), together with two of Bioventus’s subsidiaries, Bioness Inc., a Delaware corporation (“Bioness”), and Bioventus Cooperatief, U.A., a company organized under the laws of the Netherlands (“Bioventus NL”, and together with Bioventus and Bioness, collectively, the “Sellers,” and each a “Seller”), entered into a Pur…

Results of Operations and Financial Condition. On August 6, 2024, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 29, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…

Other Events. As previously disclosed, on January 12, 2023, Bioventus Inc. (the “Company” or “Bioventus”) and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina (the “Court), Ciarciello v. Bioventus, Inc., No. 1:23– CV – 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserted violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”…

Entry into a Material Definitive Agreement. On June 19, 2024, Bioventus Inc. (the “Company”) entered into an Amendment No. 1 to the Stockholders Agreement (the “Amendment”) by and among the Company, Bioventus LLC and the Principal Stockholders (as defined therein), dated as of February 1, 2021. The Amendment addresses the phasing out of the classified structure of the Company’s Board of Directors (the “Board”), as previously approved by the Company and its stockholders, and provides that memb…

Material Modification to Rights of Security Holders. The information set forth below in

Results of Operations and Financial Condition. On May 7, 2024, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 30, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Results of Operations and Financial Condition. On March 12, 2024 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act),…

Entry into a Material Definitive Agreement.. On January 18, 2024 (the “Closing Date”), Bioventus LLC (“Bioventus LLC”), a Delaware limited liability company and subsidiary of Bioventus Inc. (together with its subsidiaries, the “Company”) and certain of its subsidiaries entered into an Amendment No. 5 to the Credit and Guaranty Agreement (the “Fifth Amendment”) with Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institu…

Interim President and Chief Executive Officer — Anthony P. Bihl III: Mr. Bihl's position as Interim President and CEO was succeeded by Robert E. Claypoole, indicating a genuine departure.

President and Chief Executive Officer — Robert E. Claypoole: The company appointed a new CEO and President from an external source.

Results of Operations and Financial Condition. On November 7, 2023, Bioventus Inc. (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Excha…

Results of Operations and Financial Condition. On August 8, 2023, Bioventus Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended July 1, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")…